Researchers and trial sponsors should consult stakeholders through a transparent and meaningful participatory process which involves them in an early and sustained manner in the design,development,implementation,monitoring and distribution of results of biomedical HIV prevention trials,and participation of individuals should be voluntary and selection of participating communities and individuals must be fair and justified in terms of the scientific goals of the research.